F
Frank Friedlos
Researcher at Institute of Cancer Research
Publications - 58
Citations - 3961
Frank Friedlos is an academic researcher from Institute of Cancer Research. The author has contributed to research in topics: Prodrug & Carboxypeptidase-G2. The author has an hindex of 34, co-authored 58 publications receiving 3868 citations.
Papers
More filters
Journal Article
Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA.
TL;DR: It was concluded that the CBDCA ligand becomes a more labile leaving group once carboplatin has been monoaquated, and both chloro-ligands of cisplatin were shown to leave at similar rates, while certain cell lines were showed to be much more sensitive to DNA bound platinum.
Journal ArticleDOI
B-RAF is a therapeutic target in melanoma.
Maria Karasarides,Antonio Chiloeches,Robert Hayward,Dan Niculescu-Duvaz,Ian Scanlon,Frank Friedlos,Lesley Ogilvie,Douglas Hedley,Jan Martin,Christopher J. Marshall,Caroline J. Springer,Richard Marais +11 more
TL;DR: It is demonstrated that oncogenic B-RAF activates ERK signalling, induces proliferation and protects cells from apoptosis, demonstrating that it is an important therapeutic target and thus provides novel strategies for clinical management of melanoma and other cancers.
Journal ArticleDOI
Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin.
Silvy da Rocha Dias,Frank Friedlos,Yvonne Light,Caroline J. Springer,Paul Workman,Richard Marais +5 more
TL;DR: The data show that B-RAF is an important target for 17-AAG in human cancer, and it is shown that (V600E)B-RAf is an Hsp90 client protein that requires HSp90 for its folding and stability.
Journal ArticleDOI
The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954)--I. Purification and properties of a nitroreductase enzyme from Escherichia coli--a potential enzyme for antibody-directed enzyme prodrug therapy (ADEPT).
Gillian M. Anlezark,Roger G. Melton,Roger F. Sherwood,B Coles,Frank Friedlos,Richard J. Knox +5 more
TL;DR: Partial protein sequence analysis showed extensive homology with the "classical nit mirroreductase" of Salmonella typhimurium and a nitroreductase induced in Enterobacter cloacae.
Journal ArticleDOI
A new cytotoxic, DNA interstrand crosslinking agent, 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide, is formed from 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by a nitroreductase enzyme in Walker carcinoma cells.
TL;DR: A new compound can form interstrand crosslinks in the DNA of Chinese hamster V79 cells to which it is also highly toxic, findings indicative of the formation by Walker cells of a diffusible toxic metabolite of CB 1954.